Assembly Biosciences appoints Nobel laureate Dr. Michael Houghton to board

ASSEMBLY BIOSCIENCES, INC.

Dr. Michael Houghton, 2020 Nobel Prize winner for HCV discovery, joins as independent director.
Board expands from eight to nine members; Houghton also joins Science and Technology Committee.
Houghton received an option for 30,000 shares vesting in three equal annual installments.
He brings 40+ years of virology and drug development experience, focusing on HBV curative therapies.
CEO John McHutchison expects his expertise to be invaluable for finite HBV therapy approach.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael Houghton

Director

ASMB · ASSEMBLY BIOSCIENCES, INC.

Effective: 2021-07-19
Filed: July 20, 2021, 7:59 PM ET

On July 19, 2021, the Board of Directors (the “Board”) of Assembly Biosciences, Inc. (the “Company”) appointed Michael Houghton, Ph.D. as an independent, non-employee member of the Board effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Houghton was appointed as Director at ASSEMBLY BIOSCIENCES, INC..

Action: appointed
Role: Director

Exact text from the filing

On July 19, 2021, the Board of Directors (the “Board”) of Assembly Biosciences, Inc. (the “Company”) appointed Michael Houghton, Ph.D. as an independent, non-employee member of the Board effective immediately.

View on SEC.gov

ASSEMBLY BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001564590-21-037262

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.